Clin Osteol 2016; 21(2): 36-41

Osteoporosis and diabetes mellitus - pathogenesisGuidelines

M. Žurek, P. Horák

Keywords: diabetes mellitus, deficit inzulinu, hyperglykemie, pr ziko pádu, antidiabetická medikace v SUMMARY

Published: December 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žurek M, Horák P. Osteoporosis and diabetes mellitus - pathogenesis. Osteologický bulletin. 2016;21(2):36-41.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vestergaard P. Diabetes and Bone. J Diabetes Metab 2012;1:1-7. Go to original source...
    2. Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes 226:477-483.
    3. McCabe LR. Understanding the pathology a ne loss. J Cell Biochem 2007;102:1343-1357. Go to original source...
    4. Jehle PM, Jehle DR, Mohan S, Bohm BO. Serum levels of insulin-like growth f tor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol 1998;159:297-306. Go to original source...
    5. Saito M, Marumo K. Collagen cross-links as a determinant ofbone quality: A pos­ sible explanation for bone frag Osteoporos Int 2010;21:195-214. Go to original source...
    6. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen mo tion. J Biol Chem 2007;282:5691-5703. Go to original source...
    7. Jiajue R, Jiang Y, Wang O, Li M, Xing X, Cui L et al. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese post pausal Chinese women with type 2 diabetes mellitus. Osteoporos Int 2014; 25:1999-2005. Go to original source...
    8. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C et al. Endocrine Regulation of Energy Metabolism by the Skeleton. Cell 2007;130:456-469. Go to original source...
    9. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elde Swedish men. J Bone Miner Res 2009;24:785-791. Go to original source...
    10. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Publishing Group; Nat Rev Immunol 2011;11:98-107. Go to original source...
    11. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen mo tion. J Biol Chem 2007;282:5691-5703. Go to original source...
    12. Jiajue R, Jiang Y, Wang O, Li M, Xing X, Cui L et al. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese post pausal Chinese women with type 2 diabetes mellitus. Osteoporos Int 2014;25: 1999-2005. Go to original source...
    13. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involve diabetes mellitus. Diabetes Metab Res Rev 2004;20:196-204. Go to original source...
    14. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C et al siglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007;30:RC26-30. Go to original source...
    15. Fulzele K, Clemens TL. Novel functions for insulin in bone. Bone Elsevier 2012;50:452-456. Go to original source...
    16. Inzerillo AM, Epstein S. Osteoporosis and Diabetes Mellitus Introduction: Background. Rev Endocr Metab Disord 2004;5:261-268. Go to original source...
    17. Lu H, Kraut D, Gerstenfeld LC, Graves DT. Diabetes interferes with the bone for­ mation by affecting the expression of transcription factors that regulate osteobl differentiation. Endocrinology 2003;144:346-352. Go to original source...
    18. Phornphutkul C, Wu K-Y, Gruppuso PA The role of insulin in chondrogenesis. Mol Cell Endocrinol 2006;249:107-115. Go to original source...
    19. Conover CA, Lee PD, Riggs BL, Powell DR. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glu­ cocorticoid. Endocrinology 1996;137:3295-3301. Go to original source...
    20. Kawai M, Rosen CJ. Insulin-like growth factor-I and bone: lessons from mice men. Pediatr Nephrol 2009;24:1277-1285. Go to original source...
    21. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devi­ talized bone particles. J Am Soc Nephrol 1997;8:260-270. Go to original source...
    22. Bouxsein ML, Rosen CJ, Turner CH, Ackert CL, Shultz KL, Donahue LR et al. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mi vo. J Bone Miner Res 2002;17:500-579. Go to original source...
    23. Hie M, Iitsuka N, Otsuka T, Tsukamoto I. Insulin-dependent diabetes mellitus de­ creases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Med 2011;28:455-462.
    24. Hamann C, Kirschner S, Gunther K-P, Hofbauer LC. Bone, sweet bone-osteopo­ rotic fractures in diabetes mellitus. Nat Rev Endocrinol 2012;8:297-305. Go to original source...
    25. Moseley KF. Type Obes 2012;19:128-135. Go to original source...
    26. Yamagishi S. Role of advanced glycation en diabetes. Curr Drug Targets 2011;12:2096-2102. Go to original source...
    27. FraserJHE, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not peroxide, stimulates bone resorption in mouse calvariae. Bone 1996;19:223-226. Go to original source...
    28. García-Hernández A, Arzate H, Gil-Chavarría I, Rojo R, Moreno-Fierros L. High glucose concentrations alter cells. Bone 2012;50:276-288. Go to original source...
    29. Wu Y, Yu T, Zhang X, Liu Y, Li F, Wang YY et al. 1,25(OH)2D3 inhibits the leterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling. J Steroid Biochem Mol Biol 2012;132: 112-119. Go to original source...
    30. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis fac­ tor-alpha plasma level in patients with type 1 diabetes mellitus and its associ with glycaemic control and cardiovascular risk factors. J Intern Med 2000; 248:67-76. Go to original source...
    31. Gonzalez Y, Herrera MT, Soldevila G, Garcia-Garcia L, Perez-Armendariz EM, Fabian G et al. High glucose concentrations induce TNF-alpha production through the down-regulation of CD33 in primary human monocytes. BMC Immunol 2012;13:19. Go to original source...
    32. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM et al. Oxidative stress inhibits teoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 2004;314:197-207. Go to original source...
    33. Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N. Effects of glucose and its modulation by insulin and estradiol on BMSC differen­ tiation into osteoblastic lineages. Biochem Cell Biol 2006;84:93-101. Go to original source...
    34. Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes, KB. The lin­ kage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract 2013;99:85-92. Go to original source...
    35. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia as ciated with non-insulin-dependent mellitus: what are the causes of diabetes. Diabetes Res Clin Pract 1994;23:43-54. Go to original source...
    36. Garnero P, Borel O, Gineyts E, DuboeufF, Solberg H, Bouxsein ML, Christiansen C, Delmas PD. Extracellular post-translational modifications of collagen are ma­ jor determinants of biomechanical propertiesof fetal bovine cortical bone. Bone 2006;38:300-309. Go to original source...
    37. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984;81:583-588. Go to original source...
    38. Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van der Ham F et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 2005;37:825-832. Go to original source...
    39. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002;31:1-7. Go to original source...
    40. Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I et al. Contribution ofthe advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar ver­ tebrae. Bone 2006;39:1073-1079. Go to original source...
    41. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pento­ sidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:1013-1019. Go to original source...
    42. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR et al. Pentosidine and increased fracture risk in older adults with type 2 diab J Clin Endocrinol Metab 2009;94:2380-2386. Go to original source...
    43. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate different J Bone Miner Res 2005;20:1647-1658. Go to original source...
    44. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects human osteoblasts in vitro. Ann NY Acad Sci 2008;1126:166-172. Go to original source...
    45. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation end products interfere with integrin-mediated osteoblastic attachment to a type-I col­ lagen matrix. Int J Biochem Cell Biol 2004;36:840-848. Go to original source...
    46. Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin N Am 2013;42:697-719. Go to original source...
    47. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011;12:2096-2102. Go to original source...
    48. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular sig­ nalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013;25:2185-2197. Go to original source...
    49. Catalfamo DL, Britten TM, Storch DL, Calderon NL, Sorenson HL, Wallet SM. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteo­ clast function. Oral Dis 2013;19:303-312. Go to original source...
    50. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase ex­ pression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010;59:249-255. Go to original source...
    51. Nkolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the between metabolism and the immune system in type 2 diabetes. Genes Immun 2011;12:239-250. Go to original source...
    52. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the develop­ ment of type 2 dia 2003;52:1799-1805. Go to original source...
    53. Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels v sus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013;17: 1631-1635.
    54. Chang J, Wang Z, Tang E et al. Inhibition of osteoblastic bone formatio clear factor-kappaB. Nat Med 2009;15:682-689. Go to original source...
    55. Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contribu 477-483.
    56. Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: The boneconnection. J Intern Med 2012;272:317-329. Go to original source...
    57. Rodríguez JP, Montecinos L, Ríos S, Reyes P, Martinez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellu matrix favoring adipogenic differentiation. J Cell Biochem 2000;79:557-565. Go to original source...
    58. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bo­ ne metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009;160:265-273. Go to original source...
    59. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ. Activation of peroxisome proliferatoractivated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endo­ crinology 2007;148:903-910. Go to original source...
    60. Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS, Rosen CJ et al. Marrow fat and bone-new perspectives. J Clin Endocrinol Metab 2013; 98:935-945. Go to original source...
    61. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from a Dia Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851. Go to original source...
    62. Svoren BM, Volkening LK, Wood JR, Laffel LMB. Significant vitamin D defi­ ciency in youth with type 1 diabetes mellitus. J Pediatr Elsevier 2009;154: 132-134. Go to original source...
    63. Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF, Bates A. The prevalence of vitamin D abnormalities in Sou Int J Clin Pr 2010;64:351-355. Go to original source...
    64. Pittas A, Lau J, Hu F, Dawson-Hughes B. Review: the role of vitamin D and cal­ cium in type 2 diabetes. Metab 2007;92:2017-2029. Go to original source...
    65. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T et al. Poor g cemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 betes. Osteoporos Int 1999;9:525-531. Go to original source...
    66. Bonds DE, Larson JC, Schwartz A V, Strotmeyer ES, Robbins J, Rodriguez BL et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-3410. Go to original source...
    67. P^tel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A et al. Risk Factors for Fractures and Fall Int 2008;82:87-91.
    68. Park SW, Goodpaster BH, Strotmeyer ES et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body compo tion study. Diabetes 2006;55:1813-1818. Go to original source...
    69. Moseley KF, Dobrosielski DA, Stewart KJ, Sellmeyer DE, Jan De Beur SM. Lean mass predicts hip geometry in men and women with non-insulinrequiring type 2 diabetes mellitus. J Clin Densitom 2011;14:332-339. Go to original source...
    70. Balducci S, Sacchetti M, Orlando G, Salvi L, Pugliese L, Salerno G et al. Correlates of muscle strength in diabetes: The study on the assessment of d minants of muscle and bone strength abnormalities in diabetes (SAMBA). Nutr Metab Cardiovasc Dis 2014;24:18-26. Go to original source...
    71. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM et al. Interventions for preventing falls in older people living in the commun Cochrane database. Syst Rev 2012;9. Go to original source...
    72. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358: 2545-2559. Go to original source...
    73. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. Diabetes is as­ sociated independently ofbody composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19:1084-1091. Go to original source...
    74. Roman de Mettelinge T, Cambier D, Calders P, Van Den Noortgate N, Delbaere K. Understanding the Relationship between Type 2 Diabetes Mellitus and Falls in Older Adults: A Prospective Cohort Study. PLoS One 2013;8:2-6. Go to original source...
    75. Pijpers E, Ferreira I, de Jongh RT et al. Older individuals with diabetes have increased risk of recurrent falls: analysis of potential mediating factors: the Longitudinal Ageing Study Amsterdam. Age Ageing 2012;41:358-365. Go to original source...
    76. Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi­ ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 2010;25:141-146. Go to original source...
    77. Thrailkill KM, Lumpkin CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an ana­ bolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005;289:E735-45. Go to original source...
    78. Follak N, Kloting I, Wolf E, Merk H. Improving metabolic control reverses the stomorphometric and biomechanical abnormalities of an experimentally induced bone defect in spontaneously diabetic rats. Calcif Tissue Int 2004;74:551-560. Go to original source...
    79. McNair P, Madsbad S, Christensen MS, Christiansen C, Faber OK, Binder C et al. Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol 1979;90:463^72. Go to original source...
    80. Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García Cervigón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000;11:455-459. Go to original source...
    81. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613. Go to original source...
    82. Bazelier MT, Gallagher AM, van Staa TP et al. Use ofthiazolidinediones a of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf 2012; 21:507-514. Go to original source...
    83. Colhoun HM, Livingstone SJ, Looker HC et al. Hospitalised hip fracture risk rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929-2937. Go to original source...
    84. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR et al. Activation of peroxisome proliferator-activated receptor gam­ ma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007;148: 903-910. Go to original source...
    85. Singh R, Bhasin S, Braga M, Artaza JN, Parvin S, Taylor WE et al. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta signaling path­ ways. Endocrinology 2009;150:1259-1268. Go to original source...
    86. Vierhapper H, Nowontny P, Waldhäusl W. Reduced production rates of testoste­ rone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 2003;52:230-232. Go to original source...
    87. Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, Josse RG, Schnall AM, Simmons DL, Hue TF, Palermo L, Hamilton BP, Green JB, Atkinson HH, O'Connor PJ, Force RW, Bauer DC. Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial. Diabetes Care 2012;35:1525-1531. Go to original source...
    88. Puar TH, Khoo JJ, Cho LW, Xu Y, Chen YT, Chuo AM et al. Association between glycemic control and hip fracture. J Am Geriatr Soc 2012;60:1493-1497. Go to original source...
    89. Ljunggren O, Bolinder J, Johansson L et al. Dapagliflozin has no effect on mar­ kers of bone formation and resorption or bone mineral density in patients adequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-999. Go to original source...
    90. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta trials. Diabetes Res Clin Pract 2014;103:269-275. Go to original source...
    91. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhi­ bitors and bone fractures: a meta-analysis of randomized clinical trials. Diabe Care 2011;34:2474-2476. Go to original source...
    92. Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging 2013;30:527-547. Go to original source...
    93. Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sita tin in postmenopausal diabetic women. J Bone Miner Metab 2015;33:207-212. Go to original source...
    94. Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 2013; 28:1641-1652. Go to original source...
    95. Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactiva­ tion of Runx2. Bone Elsevier Inc 2011;48:885-893. Go to original source...
    96. Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin a tin in postmenopausal diabetic women. J Bone Miner Metab 2015;33:207-212. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.